Search
Company Statements Media Contact Email Alerts
Events & Presentations Financials Stock Information Governance Resources
Patients Team Community Environment Compliance & Transparency
Our Locations Medical Information
magnifying glass icon
Incyte
  • Our Company
  • What We Do
  • Culture & Careers
  • Patient Resources
  • HCP Resources
  • Our Stories
  • Our Company
    • Our Leadership
  • What We Do
    • Portfolio
      • Molecules in Development
      • Clinical Trials
    • Oncology
      • Approved Therapies
      • HCP Resources
    • Dermatology
      • Approved Therapies
      • HCP Resources
    • Partnerships
  • Culture & Careers
    • Open Positions
    • Incyte Involved
    • Inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  • magnifying glass icon
  • Our Company
    • magnifying glass icon
    • our company
    • our leadership
  • What We Do
    • magnifying glass icon
    • what we do
    • portfolio
    • oncology
    • dermatology
    • partnerships
  • Culture & Careers
    • magnifying glass icon
    • culture & careers
    • open positions
    • incyte involved
    • inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  • News
    • magnifying glass icon< input type = 'text' class='searchInputContainer-cust search-input-mobile' placeholder='Search' autofocus=''>
    • our company
    • Company Statements
    • Media Contact
    • E-Mail Alerts
  • Investors
    • magnifying glass icon< input type = 'text' class='searchInputContainer-cust search-input-mobile' placeholder='Search' autofocus=''>
    • our company
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • magnifying glass icon< input type = 'text' class='searchInputContainer-cust search-input-mobile' placeholder='Search' autofocus=''>
    • Patients
    • Team
    • Community
    • Environment
    • Compliance & Transparency
  • Contact Us
    • magnifying glass icon< input type = 'text' class='searchInputContainer-cust search-input-mobile' placeholder='Search' autofocus=''>
    • our company
    • Our Locations
    • Medical Information
  • United States

Incyte International Locations

NORTH AMERICA—
HEADQUARTERS

DENMARK

ITALY

SPAIN

UNITED KINGDOM

EUROPE—
HEADQUARTERS

FINLAND

JAPAN

SWEDEN

AUSTRIA

FRANCE

THE NETHERLANDS

SWITZERLAND

CANADA

GERMANY

NORWAY

PORTUGAL

Close

Home breadcrumb separator Our Storiesbreadcrumb separatorStory1
Back
Three research scientists

Innovating for Tomorrow

In 2002, a small group of research scientists, chemists and biologists working in immunology formed a drug discovery and development team. They shared a vision of creating a biopharmaceutical company willing to tackle difficult medical problems, with the end goal of making a significant impact for patients.

Twenty years later, this focus remains unchanged. For Incyte, it has, and always will be, about following the science. If we believe we have a meaningful solution for a medical need, we will pursue it—even if it is for a rare indication.

Building on our heritage and deep understanding of the impact of the immune system on disease, the result of these efforts has been profound. We focus on developing medicines in areas we can provide benefit beyond the current standard of care, or areas of need with limited or no options. These efforts have resulted in multiple therapies for patients in Oncology and Inflammation & Autoimmunity, including several that have been the first approved medicines in their class or indication.

Looking ahead, we hope to expand our pipeline and advance our key clinical programs in areas of significant unmet need. We are progressing a number of Phase 2 and Phase 3 clinical trials in a program called LIMBER. LIMBER was designed to evaluate ruxolitinib combination strategies—as well as monotherapy strategies for other compounds—for patients with myeloproliferative neoplasms (MPNs), a group of rare, chronic and progressive blood cancers, and graft-versus-host disease (GVHD). Additionally, in 2022 we have multiple key development programs progressing and anticipate important new data from our pipeline. This year we also received approval in the U.S. of the first and only FDA-approved product for repigmentation in nonsegmental vitiligo, a chronic autoimmune condition that affects millions of people and is characterized by depigmentation of skin. We expect a regulatory decision in Europe for this therapy sometime next year.

Reflecting the growth of our portfolio, our team has grown over the last 20 years to capitalize on these opportunities. Today, we are 2,200 employees strong, with a growing footprint at our headquarters in Wilmington, Delaware, and established offices across North America, Europe and Asia. We have expanded our laboratories and manufacturing facilities, ensuring we have access to the most state-of-the-art tools and technology as we work to identify innovative new therapies for patients.

We are excited to share more about who we are as a company and our drive to help patient communities in new and different ways. We invite you to visit Solve On. Stories to join us on the journey as we continue to Solve On.

We can’t wait to see what the next 20 years of scientific excellence and innovation will bring.

Related Content

What Can JAK Inhibition Do? More Than You Might Think.

Graphic of a phospholipid bilayer with JAK1, JAK2 and STAT1

View Story

A Day in the Life—Dija Atta

 

Dija Atta, Senior Director of Clinical Operations, Incyte

View Story

You are now leaving Incyte.com

DO YOU WANT TO CONTINUE?

YES, Take Me There
NO, I Changed My Mind
Incyte © 2012-2023 Incyte.
  • Facebook Icon
  • LinkedIn Icon
  • Twitter Icon
  • Youtube Icon
  • Legal Notice
  • Privacy Policy
  • Cookie Policy
  • Site Map